Evidence map›Paper›PMID 35582169›Full record

ArticleKidney3602022

Explainable Biomarkers for Automated Glomerular and Patient-Level Disease Classification.

Matthew Nicholas Basso, Moumita Barua, Rohan John, April Khademi

Open access · diamondAbstract read
In one paragraph

Article in Kidney360, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Machine learning in renal pathology.Frontiers in nephrology · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Matthew Nicholas BassoImage Analysis in Medicine Lab (IAMLAB), Department of Electrical, Computer, and Biomedical Engineering, Ryerson University, Toronto, Canada.ORCID 0000-0002-0313-3111
Moumita BaruaDivision of Nephrology, University Health Network, Toronto, Canada.
Rohan JohnDepartment of Pathology, University Health Network, Toronto, Canada.
April KhademiImage Analysis in Medicine Lab (IAMLAB), Department of Electrical, Computer, and Biomedical Engineering, Ryerson University, Toronto, Canada.
University Health Network · CASt. Michael's Hospital · CAToronto Metropolitan University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathologists use multiple microscopy modalities to assess renal biopsy specimens. Besides usual diagnostic features, some changes are too subtle to be properly defined. Computational approaches have the potential to systematically quantitate subvisual clues, provide pathogenetic insight, and link to clinical outcomes. To this end, a proof-of-principle study is presented demonstrating that explainable biomarkers through machine learning can distinguish between glomerular disorders at the light-microscopy level. The proposed system used image analysis techniques and extracted 233 explainable biomarkers related to color, morphology, and microstructural texture. Traditional machine learning was then used to classify minimal change disease (MCD), membranous nephropathy (MN), and thin basement membrane nephropathy (TBMN) diseases on a glomerular and patient-level basis. The final model combined the Gini feature importance set and linear discriminant analysis classifier. Six morphologic (nuclei-to-glomerular tuft area, nuclei-to-glomerular area, glomerular tuft thickness greater than ten, glomerular tuft thickness greater than three, total glomerular tuft thickness, and glomerular circularity) and four microstructural texture features (luminal contrast using wavelets, nuclei energy using wavelets, nuclei variance using color vector LBP, and glomerular correlation using GLCM) were, together, the best performing biomarkers. Accuracies of 77% and 87% were obtained for glomerular and patient-level classification, respectively. Computational methods, using explainable glomerular biomarkers, have diagnostic value and are compatible with our existing knowledge of disease pathogenesis. Furthermore, this algorithm can be applied to clinical datasets for novel prognostic and mechanistic biomarker discovery.

Indexed as

Glomerulonephritis, MembranousNephrosis, LipoidBiomarkersHematuriaHumansKidney GlomerulusBiomarkersbasic sciencecomputational pathologyexplainable biomarkersglomerular and tubulointerstitial diseasesmachine learningmembranous nephropathyminimal change diseasethin-basement membrane nephropathy

Identifiers

PMID35582169
PMCPMC9034815
OpenAlexW4200059501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.